Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799725 | 0.89 | GAA (0.46) | HCRTR1 | |
| SCHEMBL16372345 | 0.87 | GAA (0.53) | HCRTR1POLBKMT2A | |
| SCHEMBL17799678 | 0.87 | GAA (0.53) | HCRTR1POLBKMT2A | |
| SCHEMBL17799698 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2POLBKMT2A | |
| SCHEMBL17799724 | 0.86 | GAA (0.42) | HCRTR1POLB | |
| SCHEMBL16372276 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2POLBKMT2A | |
| SCHEMBL16372451 | 0.86 | GAA (0.42) | HCRTR1POLB | |
| SCHEMBL17799745 | 0.84 | KDM4E (0.49) | KDM4EKMT2A | |
| SCHEMBL17799726 | 0.83 | DPP4 (0.40) | HCRTR1POLBKMT2A | |
| SCHEMBL17799686 | 0.83 | DPP4 (0.40) | HCRTR1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | HCRTR1 57/4885HCRTR2 74/4885POLB 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.